OBJECTIVE： To evaluate the application of cost-utility analysis in health area of China in recent year. METHODS： From CNKI， Wanfang and VIP database， setting “cost utility” or “cost-utility” as“title”or “keyword”， related literatures were retrieved during Jan. 2011-Dec. 2015， with subject field of“medical science and technology”in CNKI， “medical science”in Wanfang database，“clinical medicine” “Chinese medicine” “preclinical medicine” “preventive medicine hygiene” or “pharmacy” in VIP. The comprehensive evaluation involved research design， research perspective， cost measurement， utility index and measurement method， cost-utility analysis index， discount and sensitivity analysis. RESULTS： A total of 31 literatures meeting inclusion criteria were selected， including 12 prospective studies， 9 retrospective studies， 9 Markov model studies， 1 mixed study. Thirteen literatures worked in medical institutions. Seven literatures explicitly mentioned research perspective； most literatures only measured direct cost （19 literatures） and adopted QALY as utility index （27 literatures）. Twenty eight literatures described measurement method of utility index （direct measurement， indirect measurement or literature method） in detail. More than half （16 literatures） analyzed cost-utility by using cost-utility ratio （CUR）； 7 literatures adopted incremental cost-utility ratio （ICUR） and 6 literatures adopted both CUR and ICUR. Five literatures used the threshold of ICUR. Eleven literatures described discount， and the majority was Markov model study. Sensitivity analysis was conducted in 16 literatures， among which 11 literatures adopted single factor analysis. The most commonly involved influential factor was cost， followed by utility value and discount rate. CONCLUSIONS： Cost-utility analysis has been widely used in China， but the quality and normalization of studies have much room for improvement. Learning more experiences from international researches can help to promote the quality of domestic studies， guide the practice of clinical rational use of drugs and support the government decision-making process and medical insurance payment in the future.